Operating Room, Tangshan Workers Hospital, Tangshan,
Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5730-5740. doi: 10.26355/eurrev_201907_18310.
Colorectal carcinoma (CRC) is one of the most common factors for tumor-associated mortalities globally. In recent years, microRNAs (miRNAs) have been identified as novel therapeutic biomarkers for cancer treatment. The purpose of the current study was to unravel the clinical significance and underlying molecular mechanisms of miR-760 in CRC progression.
Fifty-four pairs of CRC tissue samples and adjacent para-carcinoma tissue samples were collected from CRC patients who underwent surgical resection. We measured miR-760 expressions in CRC using quantitative Real-time polymerase chain reaction (qRT-PCR) analysis. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assays and transwell assays were performed to determine the functions of miR-760 in CRC cell proliferation, invasion and migration. Dual-luciferase reporter assays and Western blots were used to investigate the underlying molecular mechanisms. Moreover, the association between miR-760 expressions and clinicopathological features was analyzed.
In this study, the results showed that the down-regulated miR-760 expressions were related to the poor prognosis and malignant clinicopathologic features of CRC patients. Furthermore, functional assays revealed that miR-760 restoration obviously suppressed CRC cell proliferation, migration and invasion through modulating phosphatidylinositol 3-kinase/ protein kinase B (PI3K/AKT) pathway and epithelial-mesenchymal transition (EMT). FOXA1 was also considered as a functional target of miR-760 in CRC cells. Furthermore, miR-760 up-regulation also significantly repressed tumorigenesis in vivo.
These results suggested that miR-760 exerted cancer-suppressive functions in CRC, providing a therapeutic strategy for CRC treatment.
结直肠癌(CRC)是全球肿瘤相关死亡的最常见因素之一。近年来,microRNAs(miRNAs)已被确定为癌症治疗的新型治疗生物标志物。本研究旨在揭示 miR-760 在 CRC 进展中的临床意义和潜在分子机制。
收集 54 对接受手术切除的 CRC 患者的 CRC 组织样本和相邻癌旁组织样本。我们使用定量实时聚合酶链反应(qRT-PCR)分析测量 CRC 中的 miR-760 表达。MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐)测定和 Transwell 测定用于确定 miR-760 在 CRC 细胞增殖、侵袭和迁移中的功能。双荧光素酶报告基因测定和 Western blot 用于研究潜在的分子机制。此外,还分析了 miR-760 表达与临床病理特征之间的关系。
本研究结果表明,下调的 miR-760 表达与 CRC 患者的不良预后和恶性临床病理特征相关。此外,功能测定表明,miR-760 恢复通过调节磷脂酰肌醇 3-激酶/蛋白激酶 B(PI3K/AKT)途径和上皮-间充质转化(EMT)明显抑制 CRC 细胞的增殖、迁移和侵袭。FOXA1 也被认为是 CRC 细胞中 miR-760 的功能靶标。此外,miR-760 的上调也显著抑制了体内肿瘤发生。
这些结果表明,miR-760 在 CRC 中发挥抑癌作用,为 CRC 治疗提供了一种治疗策略。